Signum Biosciences, Inc. Announces Commercial Launch of Arazine(TM)

Proprietary skincare technology platform reaches market

PRINCETON, New Jersey, July 13, 2010 - Signum Biosciences announced that its partner, Rohto Pharmaceutical Co.,
Ltd., has launched AFC Medirepair(R) with Signum's compound Arazine(TM)
(n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine(TM) is the first
compound from Signum's novel anti-inflammatory platform to be commercialized
from Signum's pipeline of Signal Transduction Modulators (STMs). The DRx AFC
Medirepair(R) website can be found at: www.drx-web.com/aa/prod_afc.htm
.

"We're excited to launch Arazine(TM) in the Japanese market providing a
completely new and effective product for treating skin inflammation," said
Signum president, Maxwell Stock. "The commercialization of Arazine(TM) is a
significant milestone for Signum and validates our underlying business
model."

Arazine(TM) is a Signal Transduction Modulator (STM) with
anti-inflammatory properties, which has been developed for topical skin
treatment. STMs block inflammation and neutrophil infiltration in chronic
redness, acne, skin irritation, and other skin conditions by modulating
G-protein signal transduction pathways. They also act as antioxidants to
neutralize free radicals and prevent UV damage, cellular degeneration and
production of chemicals that cause further damage. Arazine(TM) is closely
followed by Signum's pipeline of compounds including SIG990 which is being
developed for rosacea and other inflammatory skin conditions.

Signum and Rohto announced their strategic alliance to develop and
commercialize skincare products in Japan during 2008. Rohto gained
semi-exclusive rights to develop and sell products in Japan that contain
Signum's anti-inflammatory compound Arazine(TM).

About Signum Biosciences.

Signum Biosciences is a private biotechnology company dedicated to
developing small-molecule therapeutics derived from its Signal Transduction
Modulation (STM) platform to modulate signal transduction imbalances. Through
research on protein networks that control biological systems, Signum is
developing therapeutic candidates for Alzheimer's, Parkinson's, diabetes,
asthma and certain skin conditions. Signum's STM technology provides many
opportunities for the development of novel consumer products and
pharmaceutical candidates.

For more information please visit the Signum website:
www.signumbiosciences.com

About Rohto Pharmaceutical Co., Ltd.

Rohto Pharmaceutical Co., Ltd. is among the largest manufacturers and
marketers of pharmaceutical and other healthcare products in Japan. Founded
in 1899, the company is based in Osaka, Japan. Production sites include
facilities in the U.S., Europe, Latin America, China and Southeast Asia with
product distribution to over 150 countries including all of Asia, the
Americas and Europe. In 1988 the company acquired management rights to
prominent U.S. manufacturer, The Mentholatum Company, Inc. Corporate sales
revenue in the latest fiscal year exceeded US$ 1 Billion. The Chairman and
CEO is Mr. Kunio Yamada.

For more information please visit the Rohto website:
www.rohto.co.jp/global

Alex Monteith of Signum Biosciences, +1-732-329-6344 ext. 204, amonteith at signumbio.com